Natacha Gaillard

Title: Natacha Gaillard and Research on Targeting Protozoan Tubulin.

Introduction

Natacha Gaillard is an inventor associated with Endingen, Switzerland, and the Paul Scherrer Institute. Her patent work concerns parabulin as a potential means of targeting protozoan tubulin and inhibiting parasite replication.

Latest Patents

Gaillard is associated with one patent, titled “Use of Parabulin for Targeting Protozoan Tubulin for the Inhibition of Protozoan Replication.” The work identifies apicomplexan tubulin, an essential component of certain parasites, as a potential drug target. It describes using parabulin or its derivatives to destabilize parasite microtubules and inhibit processes involved in replication and host-cell invasion, while aiming to avoid harm to the mammalian host.

The patent identifies parabulin as having a molecular weight of 373.4 Da and gives its chemical name as 3-(3,4-dimethoxyphenyl)-N-[(3,4,5-trimethoxyphenyl)methyl]prop-2-enamide. The proposed approach may offer a strategy for addressing the development of drug resistance.

Career Highlights

Gaillard’s listed patent activity connects her work with research at the Paul Scherrer Institute. Her contribution focuses on a potential therapeutic strategy that selectively targets parasite structures.

Collaborations

The listed coworkers associated with Gaillard include Ashwani Sharma and Michel Steinmetz. The patent’s research direction reflects collaborative scientific work on parasite biology and potential drug targets.

Conclusion

Natacha Gaillard’s patent work explores parabulin as a selective approach to disrupting protozoan tubulin and inhibiting parasite replication, with the broader aim of supporting new strategies against drug resistance. Her listed portfolio includes 1 patent.